Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
PSCI 21-160: A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia
The purpose of the study is to evaluate the potential interaction between ASTX727 and venetoclax, the study drugs, evaluate the safety when the study drugs are taken together, and any potential benefits of taking the study drugs together.
Participant must be 18 years of age or older. Newly diagnosed AML by World Health Organization (WHO) 2016 criteria For Phase 1, ECOG 0-2. For Phase 2, ECOG 0-3. Projected life expectancy of at least 3 months.
Exclusion Criteria:
Known active central nervous system involvement from AML. Known active hepatitis B or C infection Known human immunodeficiency virus (HIV) infection Severe renal impairment